Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Immuto Scientific

Explore full profile

Structure-based therapeutics discovery company pioneering a novel class of tumor-specific drug targets

Cambridge, United StatesFounded 2019Biotech & Life Sciences
Valuation $25–50M Last recorded · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Immuto Scientific and the history behind them.

About Immuto Scientific

ImmuToScientific is a biotechnology startup that operates in the pharmaceutical industry, specifically in the field of drug discovery. The company has developed a proprietary platform that enables the detailed analysis of protein structures, dynamics, and interactions. This technology allows for the empirical derivation of native-state structures at an amino acid resolution for any protein or peptide, whether standalone or in a complex. This process is completed in a matter of weeks, providing a risk-free and efficient solution for pharmaceutical companies and researchers.

The company's primary clients are pharmaceutical companies and research institutions that are involved in drug discovery and development. By providing a more efficient and detailed analysis of protein structures, ImmuToScientific helps these clients to better understand their target's structure, function, and dynamics, which in turn aids in the development of more effective drugs.

ImmuToScientific's business model revolves around its proprietary platform, PLIMB. PLIMB provides high-resolution data on antibody binding, which eliminates other costly inefficiencies in the drug discovery process. This allows developers to focus on multiple high-probability leads simultaneously, saving both time and resources.

The company generates revenue by offering its services to pharmaceutical companies and research institutions. By offering a faster, more efficient method for analyzing protein structures, ImmuToScientific provides a valuable service that can potentially save its clients significant amounts of time and money in the drug discovery process.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
Cambridge, United States
Sector
Biotech & Life Sciences

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • Madworks Seed Accelerator
  • National Institutes of Health
  • Center for Technology Commercialization
  • DYDX Capital
  • WARF Ventures
  • Great Oaks Venture Capital
  • Gravity Fund
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Immuto Scientific on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immuto Scientific on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.